| __timestamp | Bio-Techne Corporation | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 91733000 |
| Thursday, January 1, 2015 | 119401000 | 87644000 |
| Friday, January 1, 2016 | 140879000 | 92365000 |
| Sunday, January 1, 2017 | 199243000 | 85656000 |
| Monday, January 1, 2018 | 240636000 | 88196000 |
| Tuesday, January 1, 2019 | 264359000 | 89971000 |
| Wednesday, January 1, 2020 | 260583000 | 93413000 |
| Friday, January 1, 2021 | 324951000 | 91355000 |
| Saturday, January 1, 2022 | 372766000 | 113676000 |
| Sunday, January 1, 2023 | 378378000 | 198366000 |
| Monday, January 1, 2024 | 396826000 | 218935000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd. have demonstrated contrasting strategies in optimizing these costs.
From 2014 to 2024, Bio-Techne's SG&A expenses surged by over 550%, reflecting a strategic investment in growth and expansion. In contrast, Taro Pharmaceutical Industries Ltd. maintained a more conservative approach, with a modest increase of around 140% during the same period.
Bio-Techne's aggressive spending strategy, peaking at nearly $400 million in 2024, suggests a focus on scaling operations and market penetration. Meanwhile, Taro's steadier trajectory, reaching approximately $219 million, indicates a disciplined cost management approach.
These differing strategies highlight the diverse paths companies can take in navigating the complexities of the pharmaceutical sector, each with its own set of risks and rewards.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Bio-Techne Corporation and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs Jazz Pharmaceuticals plc Trends and Insights
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.